Jesús
San Miguel Izquierdo
Consultor Investigador
Medical University of Lublin
Lublin, PoloniaPublications in collaboration with researchers from Medical University of Lublin (3)
2020
-
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
Blood Cancer Journal, Vol. 10, Núm. 9
2015
-
Elotuzumab therapy for relapsed or refractory multiple myeloma
New England Journal of Medicine, Vol. 373, Núm. 7, pp. 621-631
2008
-
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
New England Journal of Medicine, Vol. 359, Núm. 9, pp. 906-917